EICHORCondition: Melanoma · Non-small Cell Lung Cancer · Colorectal Cancer · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
This description comes directly from the study's public registry record.
Amanda Guo · 1-832-207-5244 · amanda.guo@innoventbio.com
William Liu · 1-917-436-6817 · william.liu01@innoventbio.com
Always discuss trial participation with your own doctor first.
| University of California, San Francisco (UCSF) | San Francisco, California, United States | Recruiting |
| Ocala Oncology Center | Ocala, Florida, United States | Recruiting |
| BRCR Medical Center | Plantation, Florida, United States | Recruiting |
| University of Kansas Medical Center (KUMC) | Fairway, Kansas, United States | Recruiting |
| Michigan Hematology & Oncology Consultants - MedOnc Dearborn | Dearborn, Michigan, United States | Recruiting |
| Michigan Hematology & Oncology Consultants - MedOnc Troy | Troy, Michigan, United States | Recruiting |
| MD Anderson Cancer Center-University of Texas | Houston, Texas, United States | Recruiting |
| Oncology Consultants P.A. | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06281678